Clementia Pharmaceuticals Inc (CMTA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Clementia Pharmaceuticals Inc (CMTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8303
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Clementia Pharmaceuticals Inc (Clementia) is a clinical stage biopharmaceutical company that focuses on the development of treatments for rare bone disorders and other diseases. Its lead product candidate Palovarotene is used for the treatment of fibrodysplasia ossificans progressiva (FOP), dry eye disease and multiple osteochondromas (MO). Palovarotene is a novel retinoic acid receptor gamma agonist, and an oral therapy that prevents the abnormal new bone formation as well as fibrosis in a variety of tissues. The company partners with pharmaceutical companies, universities and other research institutes to develop its product portfolio. It has presence in the US and Canada. Clementia is headquartered in Montreal, Quebec, Canada.

Clementia Pharmaceuticals Inc (CMTA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Clementia Pharma Secures USD60 Million Venture Financing 12
Clementia Pharma Raises USD60 Million in Venture Financing 14
Clementia Pharma Raises USD8.5 Million in Extended Series A Venture Financing 16
Clementia Pharma Raises US$20.8 Million In Series A Financing 17
Partnerships 18
Clementia Pharma Enters into Agreement with Instituto Ortopedico Rizzoli 18
Licensing Agreements 19
Clementia Pharma Enters into Licensing Agreement with Galderma R&D 19
Clementia Pharma Enters Into License Agreement With Sanford Burnham Prebys Medical 20
Clementia Pharma Enters Into Licensing Agreement With Yamaguchi University 21
Clementia Pharma Enters into Licensing Agreement with Thomas Jefferson University 22
Clementia Pharma Enters into Licensing Agreement with F. Hoffmann-La Roche 23
Equity Offering 24
Clementia Pharma Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 24
Clementia Pharma Raises USD10 Million in Private Placement of Shares 26
Clementia Pharmaceuticals Inc – Key Competitors 27
Clementia Pharmaceuticals Inc – Key Employees 28
Clementia Pharmaceuticals Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 09, 2018: Clementia Pharmaceuticals announces second quarter 2018 financial results 30
May 09, 2018: Clementia Reports First Quarter 2018 Operating Results and Pipeline Updates 31
Feb 28, 2018: Clementia Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial Results 32
Nov 13, 2017: Clementia Reports Third Quarter 2017 Financial Results and Business Highlights 33
Corporate Communications 34
Jul 13, 2018: Clementia Names Steve Forte As Chief Financial Officer 34
Jul 05, 2018: Clementia Names Shawn Tomasello Board Director 35
Jan 31, 2018: Clementia Appoints Pierre Legault As Board Director 36
Product News 37
06/05/2017: Clementia Pharmaceuticals to Host Symposium at the 8th International Conference on Children’s Bone Health 37
Clinical Trials 38
Dec 12, 2017: Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva 38
Nov 20, 2017: Preclinical study demonstrates promising treatment for rare bone disease 39
Aug 31, 2017: Clementia Announces Data Presentations at Upcoming Medical Conferences in September 40
Mar 28, 2017: Phase 2 Part A Open Label Extension Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva Continues Positive Trends 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Clementia Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Clementia Pharma Secures USD60 Million Venture Financing 12
Clementia Pharma Raises USD60 Million in Venture Financing 14
Clementia Pharma Raises USD8.5 Million in Extended Series A Venture Financing 16
Clementia Pharma Raises US$20.8 Million In Series A Financing 17
Clementia Pharma Enters into Agreement with Instituto Ortopedico Rizzoli 18
Clementia Pharma Enters into Licensing Agreement with Galderma R&D 19
Clementia Pharma Enters Into License Agreement With Sanford Burnham Prebys Medical 20
Clementia Pharma Enters Into Licensing Agreement With Yamaguchi University 21
Clementia Pharma Enters into Licensing Agreement with Thomas Jefferson University 22
Clementia Pharma Enters into Licensing Agreement with F. Hoffmann-La Roche 23
Clementia Pharma Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 24
Clementia Pharma Raises USD10 Million in Private Placement of Shares 26
Clementia Pharmaceuticals Inc, Key Competitors 27
Clementia Pharmaceuticals Inc, Key Employees 28
Clementia Pharmaceuticals Inc, Subsidiaries 29

List of Figures
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Clementia Pharmaceuticals Inc (CMTA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sheraton Seoul Palace:企業の戦略・SWOT・財務分析
    Sheraton Seoul Palace - Strategy, SWOT and Corporate Finance Report Summary Sheraton Seoul Palace - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Sysmex Corp (6869):製薬・医療:M&Aディール及び事業提携情報
    Summary Sysmex Corp (Sysmex) is a supplier of medical devices. It researches, develops, manufactures and sells instruments, reagents, and software applications that facilitate health checkups, treatment and disease management. The company offers diagnostic instruments, reagents and laboratory inform …
  • Clean Energy Fuels Corp (CLNE):石油・ガス:M&Aディール及び事業提携情報
    Summary Clean Energy Fuels Corp (Clean Energy) is an oil and gas company that offers natural gas fuel transportation services. The company’s products fuels, liquefied natural gas, compressed natural gas, renewable natural gas, and bulk fuels. It also provides storage systems, compressors, dispensers …
  • Telconet S.A.:企業の戦略的SWOT分析
    Telconet S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Nasser S. Al –Hajri Corp:企業の戦略的SWOT分析
    Nasser S. Al –Hajri Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Group 1 Automotive, Inc.:企業の戦略・SWOT・財務情報
    Group 1 Automotive, Inc. - Strategy, SWOT and Corporate Finance Report Summary Group 1 Automotive, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Guangxi Investment Group Co Ltd:電力:M&Aディール及び事業提携情報
    Summary Guangxi Investment Group Co Ltd (Guangxi Investment) is a diversified company. The company’s business segments include energy, aluminium, financial, cultural tourism, international business and medical and medical health business. Its energy business provides investments in the construction …
  • WAVE Life Sciences Ltd (WVE):製薬・医療:M&Aディール及び事業提携情報
    Summary WAVE Life Sciences Ltd (WAVE Life Sciences), formerly WAVE Life Sciences Pte Ltd is a genetic medicine company that develops stereopure nucleic acid therapies. The company's pipeline products comprise multiple oligonucleotide modalities such as exon-skipping and single-stranded RNAi, and ant …
  • Teva Pharmaceutical Industries Ltd (TEVA)-医療機器分野:企業M&A・提携分析
    Summary Teva Pharmaceutical Industries Ltd (Teva) carries out the research, development, manufacture and commercialization of generic and specialty medicines. It provides specialty medicines in central nervous system (CNS), respiratory, cancer, women’s health and other therapy areas. The company off …
  • Avivagen Inc (VIV):企業の財務・戦略的SWOT分析
    Summary Avivagen Inc (Avivagen), formerly Chemaphor Inc is a biotechnology company that provides drug development and animal healthcare products. The company develops science-based, natural health products for animals. It operates through divisions including companion animal health, food animal heal …
  • SPR Therapeutics LLC:製品パイプライン分析
    Summary SPR Therapeutics LLC (SPR Therapeutics) is a medical device company that develops and commercializes neurostimulation based therapies and medical devices. The company develops and commercializes therapies for post-surgical pain, neuropathic pain, and musculoskeletal pain. It also provides pe …
  • FPT Securities Joint Stock Company (FTS):企業の財務・戦略的SWOT分析
    FPT Securities Joint Stock Company (FTS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Attunity Ltd (ATTU):企業の財務・戦略的SWOT分析
    Summary Attunity Ltd (Attunity) is a technology company that provides data management software, cloud database replication solutions, and google cloud database tools. The company provides data management software solutions that enable access, sharing, management, and distribution of data. It offers …
  • Seven Energy International Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Seven Energy International Ltd (Seven Energy) is an oil and gas company. The company explores, develops and distributes oil and gas interests. It provides crude oil and gas. Seven Energy offers upstream oil and gas, midstream gas processing and pipeline infrastructure services. The company’s …
  • Northfork Electric Cooperative Inc:企業の戦略的SWOT分析
    Northfork Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Nippon Shokubai Co Ltd (4114):企業の財務・戦略的SWOT分析
    Nippon Shokubai Co Ltd (4114) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Itausa – Investimentos Itau S.A.:企業の戦略・SWOT・財務情報
    Itausa - Investimentos Itau S.A. - Strategy, SWOT and Corporate Finance Report Summary Itausa - Investimentos Itau S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Sharjah Electricity & Water Authority:企業の戦略的SWOT分析
    Sharjah Electricity & Water Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • G4S plc:企業の戦略・SWOT・財務情報
    G4S plc - Strategy, SWOT and Corporate Finance Report Summary G4S plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Premiere Global Services, Inc.:企業の戦略的SWOT分析
    Premiere Global Services, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆